Visit https://www.peervoice.com/FMW860 to view the entire programme with slides. After completing “Emer Joyce, MB BCh BAO, PhD - Staying Ahead of the Curve in ATTR-CM: Adapting and Advancing Our Approach to Decision-Making as the Treatment Landscape Evolves”, participants will be able to: Assess available data which may be applied to guide treatment decision-making within the evolving treatment landscape of transthyretin amyloid cardiomyopathy (ATTR-CM); Differentiate between TTR stabilisers based on existing evidence in ATTR-CM; and Apply current evidence related to the use of combination therapy in patients with ATTR-CM.

Visit https://www.peervoice.com/XSX860 to view the entire programme with slides. After completing “Alice M. Turner, MBChB, PhD - Cross-Talk Between Lung and Liver in Alpha-1 Antitrypsin Deficiency: A Call for Integrated Care”, participants will be able to: Apply current guideline recommendations for timely testing and screening for alpha-1 antitrypsin deficiency (AATD) to facilitate early diagnosis and interventions; Identify best practices and practical strategies for the collaborative monitoring and management of patients with AATD; and Assess the phase 3 landscape of investigational therapies for the treatment of liver disease associated with AATD.

Visit https://www.peervoice.com/ZUC860 to view the entire programme with slides. After completing “Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC”, participants will be able to: Utilise appropriate diagnostic technologies to overcome challenges in accurately characterising molecular alterations in patients with NTRK fusion-positive and HER2-mutant advanced NSCLC; Differentiate between precision oncology therapies used in patients’ management of NTRK fusion-positive advanced NSCLC; Distinguish between the study populations of clinical trials examining emerging targeted therapies in patients with advanced NSCLC harbouring HER2-activating mutations from studies examining other HER2 aberrations; and Describe the recent data and clinical significance associated with trials examining emerging targeted therapies in patients with advanced NSCLC harbouring HER2-activating mutations.

Visit https://www.peervoice.com/TQR860 to view the entire programme with slides. After completing “Enriqueta Felip, MD, PhD - Targeting TROP2 in Advanced NSCLC: What Do We Know From Recent Clinical Trials?”, participants will be able to: Recognise the rationale behind TROP2 as a therapeutic target in NSCLC; Recall the results of clinical trials assessing the safety and efficacy of TROP2-directed therapy across different types of NSCLC, including non-oncogene-addicted, EGFR-mutant and ALK-rearranged NSCLC; and Assess the clinical relevance of subgroup analyses evaluating the effect of TROP2-directed therapy in specific types of NSCLC (eg, EGFR-mutant NSCLC that has progressed after initial TKI therapy).

Visit https://www.peervoice.com/GWG860 to view the entire programme with slides. After completing “Solange Peters, MD, PhD - Partnering With Patients: Shared Decision-Making in Locally Advanced, Unresectable EGFR-Mutated Non-Small Cell Lung Cancer”, participants will be able to: Recognise the perspectives and concerns of patients with locally advanced, unresectable EGFR-mutated NSCLC in evaluating treatment decisions; Apply practical approaches to facilitate patient understanding of the rationale, implications, and benefits of curative intent treatment strategies in the management of locally advanced, unresectable EGFR-mutated NSCLC; and Implement practical communication approaches to support patients with locally advanced, EGFR-mutated NSCLC in making decisions about treatment.

Visit https://www.peervoice.com/MGY860 to view the entire programme with slides. After completing “Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials”, participants will be able to: Compare the study designs and endpoints of pivotal phase 3 clinical trials in transthyretin amyloid cardiomyopathy (ATTR-CM); Identify the differences in baseline characteristics of study populations in key phase 3 trials in ATTR-CM and their impact on study outcomes; and Evaluate the clinical relevance and practical applicability of available study outcomes from pivotal trials in ATTR-CM.

Visit https://www.peervoice.com/VBS860 to view the entire programme with slides. After completing “Nicoletta Policek, PhD - When You Are Not an HIV Specialist But You Are Addressing Broader Healthcare Needs of Individuals With HIV: What Do You Need to Know?”, participants will be able to: Identify strategies to improve communication between people living with HIV (PWLH) and healthcare providers (HCPs), reduce HCP stigma, and build positive perceptions of health management by non-HIV specialist HCPs; and Propose key practical preventative steps for HIV-associated comorbidities.

Visit https://www.peervoice.com/JPM860 to view the entire programme with slides. After completing “Zaeem Siddiqi, MD, PhD - Tailoring Treatment for Hereditary Transthyretin Amyloidosis Polyneuropathy: The Evolution of Care”, participants will be able to: Evaluate the latest clinical evidence of RNA-targeted therapies for hereditary transthyretin amyloidosis with polyneuropathy (hATTR PN); Formulate individualized treatment plans based on disease and patient factors; and Summarize current and emerging data for transthyretin amyloid cardiomyopathy (ATTR CM).

Visit https://www.peervoice.com/MWF860 to view the entire programme with slides. After completing “Geneviève Matte, MDCM, FRCPC - Improving Early Diagnosis of hATTR Amyloidosis: A Critical Step Towards Better Outcomes”, participants will be able to: Describe current challenges in the diagnosis of hereditary transthyretin (hATTR) amyloidosis; Outline key manifestations that should prompt screening for hATTR amyloidosis; and Discuss expert recommendations to facilitate diagnosis, including key assessments to help identify patients with hATTR amyloidosis earlier.

Visit https://www.peervoice.com/WAD860 to view the entire programme with slides. After completing “Raffaele Califano, MD - At the Frontline in ALK+ NSCLC: Practical Approaches to TKI Therapy”, participants will be able to: Describe the molecular aberrations and associated patient characteristics that influence response to treatment modalities in ALK-positive non-small cell lung cancer (NSCLC); Apply evidence-based approaches to balance the benefits of efficacy with risks of treatment-related toxicities in consolidated therapy combinations used in the management of ALK+ NSCLC; Formulate evidence-based strategies to identify and manage common and serious adverse events (AEs) associated with tyrosine kinase inhibitors (TKIs); and Apply evidence-based approaches to balance the benefit-risk ratio in the selection of appropriate treatment modalities for patients with ALK+ NSCLC and central nervous system (CNS) metastases.

Visit https://www.peervoice.com/KHV860 to view the entire programme with slides. After completing “Isabel Conceição, MD - Prioritizing Patient-Centered Care for ATTR: Expert Perspectives on the Evolution of Data and Decision-Making”, participants will be able to: Identify best practices to optimize the recognition and diagnosis of patients with transthyretin amyloidosis (ATTR), including those with ATTRv-PN and those with mixed phenotype ATTR; Evaluate current and emerging treatment options for hereditary ATTR with polyneuropathy (ATTRv-PN), including key differences between therapies with regards to clinical trial design, patient populations studied, available outcomes, and administration considerations; and Apply a comprehensive, patient-centered approach to management of patients with ATTR, including those with ATTRv-PN and those with mixed phenotype ATTR.

Visit https://www.peervoice.com/RHA860 to view the entire programme with slides. After completing “Phyllis C. Zee, MD, PhD - Sleep, Heart, Brain: What Promotes and How to Reduce Cardiovascular Risk in Patients With Narcolepsy”, participants will be able to: Describe the pathophysiology of narcolepsy in the context of cardiovascular (CV) effects; Differentiate between narcolepsy medications regarding their impact on CV risk factors; Identify medications used for common comorbidities associated with narcolepsy that have the potential to increase CV risk; and Propose strategies to manage CV risk in patients with narcolepsy.

Visit https://www.peervoice.com/DRF860 to view the entire programme with slides. After completing “Michael Thorpy, MD - When Sleep Is Exhausting: Improving Diagnosis and Outcomes in Patients With Idiopathic Hypersomnia”, participants will be able to: Recognize health risks associated with idiopathic hypersomnia; Differentiate idiopathic hypersomnia from other conditions that cause excessive daytime sleepiness (EDS); Explain how to establish a confirmatory diagnosis of idiopathic hypersomnia; and Propose effective, individualized, evidence-based management strategies for patients with idiopathic hypersomnia.

Visit https://www.peervoice.com/QHY860 to view the entire programme with slides. After completing “Jonathan W. Riess, MD, MS - The Central Role of the Pathologist in Detecting MET Alterations: Enabling Multidisciplinary Teams to Do More With Less in NSCLC”, participants will be able to: A key challenge is that physicians cannot simply order a “MET test”; different tests must be used to detect the different alterations;; Exon 14 skipping mutations, amplification, and fusion can be detected via DNA or RNA-based next-generation sequencing (NGS);; Amplification and fusion may also be detected by fluorescence in situ hybridization (FISH);; and Overexpression is detected via immunohistochemistry (IHC)..

Visit https://www.peervoice.com/UPK860 to view the entire programme with slides. After completing “Jeffrey Habert, MD, CCFP, FCFP - Steps Towards Earlier Detection of Lung Cancer: Harnessing the Power of Primary Care”, participants will be able to: Explain the rationale for screening asymptomatic patients for lung cancer based on identified eligibility criteria; Outline practical tips for primary care to screen and monitor appropriate patients for lung cancer, in order to facilitate early identification; Discuss when to investigate lung cancer in symptomatic patients; and Apply effective strategies to optimize referral into the diagnostic assessment clinic.

Visit https://www.peervoice.com/RVW860 to view the entire programme with slides. After completing “Simon Couillard, MD, MSc - Improving Outcomes in Severe Eosinophilic Asthma: Translating Recent Evidence With Biologics Into Patient Care”, participants will be able to: Discuss the pathogenic mechanisms in severe eosinophilic asthma and the role of biomarkers in informing treatment; Describe the role of biologics in improving patient outcomes and their impact on background medication use; and Outline the most recent real-world evidence with biologics for severe eosinophilic asthma and its clinical implications for patient management.

Visit https://www.peervoice.com/HPP860 to view the entire programme with slides. After completing “Jonathan W. Goldman, MD - Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC”, participants will be able to: Differentiate between pathophysiology of MET alterations in patients with NSCLC and the recommended strategies for their detection; Apply best practices to overcome challenges in the identification of patients with NSCLC and MET vulnerabilities; and Summarize current and emerging strategies for targeting MET alterations as a therapeutic vulnerability in patients with NSCLC.

Visit https://www.peervoice.com/ZFW860 to view the entire programme with slides. After completing “Wisia Wedzicha, MD, FRCP - Taking the Evidence from Paper to Practice: Shared Perspectives on Practical Considerations in Comprehensive COPD Care”, participants will be able to: Summarise key data which informs guideline-driven interventions for patients with chronic obstructive pulmonary disease (COPD); Identify treatable traits which can guide need for non-pharmacologic interventions and selection of pharmacotherapy, including triple therapy, for patients with COPD; and Use patient- and disease-specific considerations and treatable traits to guide comprehensive management strategies for patients with COPD.

Visit https://www.peervoice.com/GFE860 to view the entire programme with slides. After completing “Geoffrey Liu, MD, MSc, FRCPC, FISPE - Optimizing the Potential for Patients With ALK-Positive mNSCLC Throughout Their Treatment Journey”, participants will be able to: Discuss the importance of first-line treatment and the factors to consider when selecting a treatment strategy for patients with ALK-positive metastatic non–small-cell lung cancer (mNSCLC); Describe the evolving clinical evidence and guideline recommendations for the treatment of ALK-positive mNSCLC; Review the toxicities of the new generation tyrosine kinase inhibitors (TKIs) used as first-line in the treatment of ALK-positive mNSCLC; and Apply key learnings and strategies to enhance the toxicity management of new generation TKIs for optimal patient outcomes.

Visit https://www.peervoice.com/UWS860 to view the entire programme with slides. After completing “David M. G. Halpin, MB BS, DPhil, FERS - The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of Disability and Death”, participants will be able to: Recognise current unmet needs in the management of chronic obstructive pulmonary disease (COPD); Explain the rationale for early interventions, including both non-pharmacologic and pharmacologic, to improve control of symptoms and reduce exacerbations in patients with COPD; and Apply treatment guidelines for key non-pharmacologic and pharmacologic interventions in the management of patients with COPD.